Colorectal cancer

Lancet

Volumn 353, Issue 9150, 1999, Pages 391-399

  Midgley, R ^a   Kerr, D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; GENE THERAPY; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0033616484     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)07127-X     Document Type: Review

References (64)

1. Boyle P. Some recent developments in the epidemiology of colorectal cancer. In:Bleiberg H, Rougier P, Wilke H-J, eds. Management of Colorectal Cancer. London: Martin Dunitz, 1998: 19-34.
2. Midgley RS, Kerr DJ. Systemic adjuvant chemotherapy for colorectal cancer. In: Bleiberg H, Rougier P, Wilke H-J, eds. Management of Colorectal Cancer. London: Martin Dunitz, 1998: 126-37.
3. Vogelstein B., Fearon E.R., Hamilton S.R., et al. Genetic alterations during colorectal-tumour development. N Engl J Med. 319:1988;525-532.
4. Cawkwell L, Quirke P. The molecular biology and genetics of colorectal cancer. In: Williams NS, ed. Colorectal Cancer. London: Churchill Livingstone, 1996: 1.
5. Olschwang S., Tiret A., Laurent-Puig P., et al. Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients. Cell. 75:1993;959-968.
6. Scott R.J., van der Luijt R., Spycher M., et al. Novel germline APC mutation in a large familial adenomatous polyposis kindred displaying variable phenotypes. Gut. 36:1995;731-736.
7. Nagase H., Miyoshi Y., Horii A., et al. Correlation between the location of germline mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients. Cancer Res. 52:1992;1734-1737.
8. Morin P.J., Sparks A.B., Korinek V., et al. Activation of β-catenin-Tcf signalling in colon cancer by mutations in β-catenin or APC. Science. 275:1997;1787-1790.
9. Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet. 9:1993;391-399.
10. Lynch H.T., Smyrk T.C., Watson P., et al. Genetics, natural history, tumor spectrum and pathology of hereditary non-polyposis colorectal cancer: an updated review. Gastroenterology. 104:1993;1535-1549.
11. Vasen H.F.A., Mecklin J-P, Meera Khan P., Lynch H.T. The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum. 34:1991;424-425.
12. Fishel R., Lescoe M.K., Rao M.R.S., et al. The human mutator gene homolog MSH2 and its association with hereditary non-polyposis colon cancer. Cell. 75:1993;1215-1225.
13. Bronner C.E., Baker S.M., Morrison PTet al. Mutation in the DNA mismatch repair homolog hMLH1 is associated with hereditary non-polyposis colon cancer. Nature. 368:1994;258-261.
14. Nicolaides N.C., Papadopoulos N., Liu B., et al. Mutations of two PMS homologues in hereditary non-polyposis colorectal cancer patients. Nature. 371:1994;75-80.
15. Aaltonen L.A., Peltomaki P., Leach F.S., et al. Clues to the pathogenesis of familial colorectal cancer. Science. 260:1993;812-816.
16. Grady W., Rajput A., Myeroff L., et al. What's new with RII? Gastroenterology. 112:1997;297.
17. Akiyama Y., Iwanaga R., Saitoh K., et al. Transforming growth factor β Type II receptor gene mutations in adenomas from hereditary non-polyposis colorectal cancer. Gastroenterology. 112:1997;33.
18. Doran J., Hardcastle J.D. Bleeding patterns in colorectal cancer: the effect of aspirin and implications for faecal occult blood testing. Br J Surg. 69:1982;711-713.
19. Mandel J.S., Bond J.H., Church T.R., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 328:1993;1365-1371.
20. Winawer S.J., Andrews M., Flehinger B., et al. Progress report on controlled trial of fecal occult blood testing for the detection of colorectal neoplasia. Cancer. 45:1980;2959.
21. Kewenter J, Asztely M, Engaras B. A randomised trial of fecal occult blood testing for early detection of colorectal cancer: results of screening and re-screening of 51,325 subjects. In: Miller AB, Chamerlain J, Day NE, Kakama M, Prorok PC, eds. Cancer Screening. New York: Cambridge University Press, 1991: 118.
22. Kronborg O., Fenger C., Olsen J., et al. Randomised study of screening for colorectal cancer with faecal occult blood test. Lancet. 348:1996;1467-1471.
23. Hardcastle J.D., Chamberlain J., Robinson M.H.E., et al. Randomised controlled trial of faecal occult blood screening for colorectal cancer. Lancet. 348:1996;1472-1477.
24. Tokiue M, Yasutake K, Oya M, et al. Detection of K-Ras gene mutations in the stool sample of patients with colorectal tumours Gut 1994; 35 (suppl 4): A70 (abstr).
25. Newcomb P.A., Norfleet R.G., Surawicz T.S., Storer B.E. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst. 84:1992;1572-1575.
26. Selby J.V., Friedman G.D., Queensbury C.P., Weiss N.S. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 326:1992;653-657.
27. Ransohoff D.F., Lang C.A. Sigmoidoscopic screening in the 1990s. JAMA. 269:1993;1278.
28. Bennett DH, Hardcastle JD. Early diagnosis and screening. In: Williams N, ed. Colorectal Cancer: Clinical Surgery International. London: Churchill Livingstone, 1996: 21.
29. McArdle C., Hole D. Impact of variability among surgeons on post-operative morbidity and mortality and ultimate survival. BMJ. 302:1991;1501-1505.
30. McArdle C, Murray GD, Hole DO. Recent Advances in Surgery. In: Taylor I, Johnson CD, eds. London: Churchill Livingstone, 1998: 129-43:
31. Williams N.S., Dixon M.F., Johnston D. Reappraisal of the 5 cm rule of distal excision for carcinoma of the rectum: a study of distant intramural spread and patient survival. Br J Surg. 70:1983;150-154.
32. MacFarlane J., Ryall R., Heald R. Mesorectal excision for rectal cancer. Lancet. 341:1983;457-460.
33. Quirke P., Durdey P., Dixon M.F., Williams N.S. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection: histopathological study of lateral tumour spread and surgical excision. Lancet. ii:1986;996-999.
34. Williams N.S., Durdey P., Johnston D. The outcome following sphincter saving resection and abdominoperineal resection for low rectal cancer. Br J Surg. 72:1985;596-598.
35. Fischer DS. Follow-up Cancer. Philadelphia: Lippincott-Raven., 1996.
36. Gray R. Recurrent and advanced disease. In: Guidance on Commissioning Cancer Services: Improving Outcomes in Colorectal Cancer. London: Department of Health, 1997.
37. Kerr D.J., Lederman J.A., McArdle C., et al. Phase I clinical and pharmacokinetic study of folinic acid and infusional hepatic arterial5-fluorouracil. J Clin Oncol. 3:1995;2968-2972.
38. Moertel C.G., Fleming T.R., MacDonald J.S., et al. Levamisole and fluouracil for adjuvant treatment of resected colon cancer. N EnglJ Med. 322:1990;352-358.
39. IMPACT trial. Efficacy of adjuvant fluouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-44.
40. O'Connell M., Maillard J., Kahn M.J., et al. Controlled trial of fluouracil and low-dose leucovorin given for 6 months as post-operative adjuvant therapy for colon cancer. J Clin Oncol. 15:1997;246-250.
41. Wolmark N., Rockette H., Fisher B., et al. The benefit of leucovorin modulated 5-fluorouracil as post-operative adjuvant treatment for primary colon cancer: results from the National Surgery and Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 11:1993;1879-1888.
42. O'Connell MJ, Lauie JA, Shepherd L, et al. A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: A collaborative trial of the north central cancer treatment group and the national cancer institute of Canada clinical trials group. Proc Am Soc Clin Oncol 1996; 15: 209 (abstr).
43. Liver Infusion Meta-analysis Group Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst. 89:1997;497-505.
44. Pahlman L. Pre-opreative treatment of rectal cancer. In: Bleiberg H, Rougier P, Wilke H-J, eds. Management of Colorectal Cancer Martin Dunitz, 1997.
45. SRCT (Swedish Rectal Cancer Trial). Local recurrence rate in a randomised multicentre trial of pre-operative radiotherapy compared to surgery alone in resectable rectal cancer. Eur J Surg 1996; 162: 397-402.
46. James R.D., Haboubi N., Schofield P.F., et al. Prognostic factors in colorectal cancer treated by pre-operative radiotherapy and immediate surgery. Dis Colon Rectum. 34:1991;546-551.
47. Gerard A., Buyse M., Nordlinger B., et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Ann Surg. 208:1988;606-614.
48. SRCSG (Stockholm Rectal Cancer Study Group) Preoperative short term radiation therapy in operable rectal carcinoma. Cancer. 66:1990;49-53.
49. Balslev I., Pederson M., Teglbjaerg P.S., et al. Post-operative radiotherapy in Dukes B and C carcinoma of the rectum and rectosigmoid: a randomised multicentre study. Cancer. 58:1986;22-28.
50. GITSG (Gastro Intestinal Tumour Study Group) Prolongation of the disease-free interval in surgically treated rectal carcinoma. N EnglJ Med. 312:1985;1464-1472.
51. Fisher B., Wolmark N., Rockette H.et al. Post-operative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 80:1988;21-29.
52. MRC Rectal Cancer Working Party. Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Lancet 1996; 348: 1610-14.
53. Jansson-Frykholm G., Glimelius B., Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomised trial and an evaluation of late secondary effects. Dis Colon Rectum. 36:1993;564-572.
54. O'Connell M.J., Martenson J.A., Wieand H.S., et al. Improving adjuvant therapy for rectal cancer by combining protracted infusion fluouracil with radiation therapy after curative surgery. N Engl J Med. 331:1994;502-507.
55. Cunningham D., Zalcberg J.R., Rath U., et al. Tomudex ZD1694: results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leukopenia. Eur J Cancer. 31A:1995;1945-1954.
56. Seymour MT, Cassidy J, Wilson C, et al. Oxaliplatin, 5-fluorouracil and folinic acid first-line combination therapy in colorectal cancer: cesults of a phase III trial.ECCO meeting, 1997: (abstr).
57. Conroy T. Single agent therapy of colorectal cancer. In: Bleilerg H, Rougier P, Wilke HJ, eds. Management of Colorectal Cancer. London: Martin Dunitz, 1997.
58. Cunningham D, Pyrrhonen S, James R, et al. A phase III multicenter randomised study of CPT-11 versus best supportive care alone in patients with 5FU-resistant metastatic colorectal cancer. Proc ASCO 1998; 17: (abstr 1).
59. Riethmuller G., Scneider-Gadicke E., Schmilok G. Randomised trial of monoclonal antibody for adjuvant treatment of resected DukesC colorectal cancer. Lancet. 343:1994;1177-1183.
60. Lathe R., Kierny M.P., Gerlinger Pet al. Tumour prevention and rejection with recombinant vaccinia. Nature. 326:1989;87.
61. Cole D.J., Baron P.L., O'Brient P., Reed C., Tsang K.Y., Schlom J. Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge. Hum Gene Ther. 7:1996;1381-1394.
62. Venook A.P., Bergsland E.K., Ring Eet al. Gene therapy of colorectal liver metastases using a recombinant adenovirus encoding WT p53 (SCH 58500) via hepatic artery infusion: a phase I study. Proc ASCO. 17:1998;431a.
63. Huber B.E., Austin E.A., Good S.S., Knick V.C., Tibbel S., Richards C.A. In vivo anti-tumour activity of 5-fluorocytosine on human colorectal cancer cells genetically modified to express cytosine deaminase. Cancer Res. 53:1993;4619-4626.
64. Ferry D.R., Smith A., Fyfe Det al. Phase I trial of the flavanoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 2:1996;659-668.